Yongzhang LUO Ph.D.
Professor
1981-1985, B.S., Department of Chemistry, Lanzhou University
1989-1993, Ph.D., Department of Molecular and Cell Biology, University of California at Berkeley
1993-1994, Postdoc., Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School
1994-1998, Postdoc., Department of Biochemistry, Stanford University School of Medicine
Dr. Luo is currently a professor at the School of Life Sciences, Tsinghua University, and the director of the National Engineering Research Center for Protein Technology.
Research interest
Our lab provides a comprehensive platform spanning from basic scientific discovery to the industrial translation of high-quality recombinant protein drugs. We are committed to resolving bottlenecks in the prevention and treatment of major diseases by deciphering the fundamental logic of life.
Our research areas mainly include the following aspects:
1. Mechanisms of Aging and Anti-aging
Exploring the core pathways and systemic interventions for maintaining health span from the perspective of the fundamental logic of life.
2. Mechanisms of Neurodegenerative Diseases
Focusing on the mechanistic research and clinical trial exploration of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD).
3. Mechanisms of Metabolic and Related Diseases
Investigating the pathogenic mechanisms and clinical translation of type 2 diabetes, obesity, and lipid metabolism (featuring the original discovery of the “Albumosome”), as well as muscle atrophy and repair, osteoporosis, and rheumatoid arthritis, from a comprehensive metabolic perspective.
4. Mechanisms of Cardiovascular Diseases
Investigating the pathogenic mechanisms and clinical translation of myocardial hypertrophy, cardiac fibrosis, and atrial fibrillation.
Selected publications
1. Ma B, Ju A, Zhang S, An Q, Xu S, Liu J, Yu L, Fu Y & Luo Y*. Albumosomes formed by pre-folding albumin in cytoplasm of hepatocytes maintain mitochondrial homeostasis and inhibit nonalcoholic fatty liver disease.
Signal Transduct Target Ther. 2023;8(1):229.doi: 10.1038/s41392-023-01437-0.
2. Liu, H., Ju, A., Dong, X. et al. Young and undamaged recombinant albumin alleviates T2DM by improving hepatic glycolysis through EGFR and protecting islet β cells in mice. J Transl Med 21, 89 (2023). https://doi.org/10.1186/s12967-023-03957-3
3. Tang J, Ju A, Li B, et al. Young and Undamaged rMSA Improves the Healthspan and Lifespan of Mice. Biomolecules. 2021;11(8):1191. doi:10.3390/biom11081191
Contact information
Tel：+86-10-62794691
E-mail: protein@tsinghua.edu.cn
